Timothy Ownbey, DO
Neurology · Albuquerque, NMNPI 1386632404
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (58.9%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. AbbVie accounts for 67.1% of it on its own, with 51 other manufacturers making up the rest. Reporting peaked in 2021 at $41,838 and has fallen 93.3% since, to $2,811 in 2025. Among neurology clinicians in NM with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,317 payments — averaging $68.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$60K
- Eli Lilly$6K
- Lilly USA, LLC$3K
- Medtronic$2K
- Teva Pharmaceuticals USA, Inc.$2K
- Catalyst Pharmaceuticals, Inc.$2K
- plus $14K from 46 others
What the payments were for
- Consulting fees$7,1008%
- Speaking & faculty fees$52,74459%
- Travel & lodging$5,8497%
- Food & beverage$23,61926%
- Education$2510%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$89,563 in reported general payments places this provider in the 95th percentile of 91 neurology providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 24 | $306,247 |
| NuplazidPimavanserin Tartrate | 39 | $218,721 |
| Nurtec OdtRimegepant Sulfate | 87 | $117,940 |
| Avonex (4 Pack)Interferon Beta-1a | 13 | $103,495 |
| Aimovig AutoinjectorErenumab-Aooe | 110 | $95,120 |
| Emgality PenGalcanezumab-Gnlm | 104 | $79,095 |
| RytaryCarbidopa/Levodopa | 32 | $45,723 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 35 | $35,899 |
| XcopriCenobamate | 26 | $30,245 |
| BotoxOnabotulinumtoxina | 26 | $28,226 |
| UbrelvyUbrogepant | 21 | $27,260 |
| OngentysOpicapone | 14 | $25,306 |
| BriviactBrivaracetam | 11 | $18,139 |
| QuliptaAtogepant | 14 | $16,531 |
| Rasagiline Mesylate | 41 | $13,155 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $2,275 | $306,24724 claims |
| Acadia Pharmaceuticals IncNuplazid | $487 | $218,72139 claims |
| PfizerNurtec Odt | $806 | $117,94087 claims |
| BiogenAvonex (4 Pack) | $470 | $103,49513 claims |
| AbbVieBotox, Ubrelvy, Qulipta | $60,109 | $72,01761 claims |
| Amneal Pharmaceuticals LLCRytary | $362 | $45,72332 claims |
| SK Life Science, Inc.Xcopri | $274 | $30,24526 claims |
| Neurocrine Biosciences, Inc.Ongentys | $570 | $25,30614 claims |
| UCB, Inc.Briviact | $1,104 | $18,13911 claims |
| Lilly USA, LLCReyvow | $3,254 | $7,91911 claims |
| Upsher-smith Laboratories LLCTopiramate | $72 | $2,591169 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 91 neurology providers in New Mexico.
Other neurology in Albuquerque
- Elaine EdmondsAlbuquerque$610K
- Kader AbdelerahmanAlbuquerque$607K
- Gerson Suarez CedenoAlbuquerque$44K
- Corey FordAlbuquerque$27K
- Diksha MohantyAlbuquerque$20K
- Douglas BarrettAlbuquerque$19K
- Vanessa Licona SanjuanAlbuquerque$16K
- Daniel ShibuyaAlbuquerque$13K
- Alfred van BaakAlbuquerque$10K
- Manuel GuruleAlbuquerque$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.